{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:10:02Z","timestamp":1755846602241,"version":"3.44.0"},"publisher-location":"New York, NY, USA","reference-count":16,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"DOI":"10.1145\/3570773.3570815","type":"proceedings-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T15:57:42Z","timestamp":1670601462000},"page":"202-207","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Review of Targeted Therapy for HER-2 Positive Breast Cancer"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-8748","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"first","affiliation":[{"name":"Beijing No. 2 High School, Dong cheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"320","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"e_1_3_2_1_1_1","first-page":"78","article-title":"Progress in molecular targeted therapy for her-2 positive inflammatory breast cancer","volume":"112","author":"Wang Z.","year":"2013","unstructured":"Wang, Z. 2013. Progress in molecular targeted therapy for her-2 positive inflammatory breast cancer. Chinese Clinical Oncology, 112: 78-90.","journal-title":"Chinese Clinical Oncology"},{"key":"e_1_3_2_1_2_1","first-page":"144","article-title":"Clinical research of targeted therapy in her-2 positive metastatic breast cancer","volume":"10","author":"Hao L.","year":"2016","unstructured":"Hao, L., Hui, Z., Yang, Y., Cheng, W., & Hospital, J. T. 2016. Clinical research of targeted therapy in her-2 positive metastatic breast cancer. Journal of Modern Oncology, 10: 144-156.","journal-title":"Journal of Modern Oncology"},{"key":"e_1_3_2_1_3_1","first-page":"54","article-title":"Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 cancer care ontario systemic therapy guideline","volume":"18","author":"Mates G., G.","year":"2014","unstructured":"M., Mates, G., G., Fletcher, O., C., & Freedman, 2014. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 cancer care ontario systemic therapy guideline. Current Oncology, 18: 54-63.","journal-title":"Current Oncology"},{"issue":"3","key":"e_1_3_2_1_4_1","first-page":"101","article-title":"Production and characterization of a novel long-acting herceptin-targeted nanobubble contrast agent specific for her-2-positive breast cancers","volume":"23","author":"Jiang Q.","year":"2015","unstructured":"Jiang, Q., Hao, S., Xiao, X., Yao, J., Ou, B., & Zhao, Z., 2015. Production and characterization of a novel long-acting herceptin-targeted nanobubble contrast agent specific for her-2-positive breast cancers. Breast Cancer, 23(3): 101-118.","journal-title":"Breast Cancer"},{"key":"e_1_3_2_1_5_1","doi-asserted-by":"crossref","unstructured":"Raphael K. H. Elie E. R. Florian C. Evandro D. A. & Matteo L. 2017. Emerging treatments for her2-positive early-stage breast cancer: focus on neratinib. OncoTargets and therapy 10: 32-47.","DOI":"10.2147\/OTT.S122397"},{"key":"e_1_3_2_1_6_1","unstructured":"Jobard E. Bachelot T. & Campone M. 2016. NMR investigation of targeted therapy effects on the host metabolism for HER-2 positive breast cancer 29: 128-144."},{"key":"e_1_3_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2011-5314"},{"key":"e_1_3_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25120"},{"issue":"2","key":"e_1_3_2_1_9_1","first-page":"126","article-title":"Advances in dual-targeted therapy for her2-positive breast cancer based on trastuzumab","volume":"55","author":"Li X.","year":"2019","unstructured":"Li, X., & Ma, H. 2019. Advances in dual-targeted therapy for her2-positive breast cancer based on trastuzumab. Chinese Journal of Clinical Oncology, 55(2): 126-141.","journal-title":"Chinese Journal of Clinical Oncology"},{"issue":"3","key":"e_1_3_2_1_10_1","first-page":"24","article-title":"Current status and prospect of her-2 targeted therapy for breast cancer","volume":"98","author":"Nie W.","year":"2018","unstructured":"Nie, W., & Hospital, T. T. 2018. Current status and prospect of her-2 targeted therapy for breast cancer. Chinese Community Doctors, 98(3): 24-28.","journal-title":"Chinese Community Doctors"},{"key":"e_1_3_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-216"},{"key":"e_1_3_2_1_12_1","doi-asserted-by":"crossref","unstructured":"Naskhletashvili D. R. Roshchina K. E. Gorbunova V. A. Gasparyan T. G. & Pogosova A. 2020. Targeted therapy in the treatment of her-2 positive breast cancer with brain metastases 54: 79-92.","DOI":"10.17816\/1028-9984-2020-25-4-146-153"},{"key":"e_1_3_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000745"},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S256898"},{"key":"e_1_3_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Chen D. Tyebally S. Malloupas M. Roylance R. Spurrell E. & Raja F. 2021. Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (imrt-sib) using forward imrt or tomotherapy for breast cancer. Scientific reports 10(1) 4342.","DOI":"10.1038\/s41598-020-61403-6"},{"key":"e_1_3_2_1_16_1","first-page":"1","article-title":"Trastuzumab, pertuzumab, and docetaxel as the first line for her-2-positive metastatic breast cancer among arabs","author":"Suleman K.","year":"2020","unstructured":"Suleman, K., Mushtaq, A. H., Haque, E., Badran, A. A., & Alsayed, A. 2020. Trastuzumab, pertuzumab, and docetaxel as the first line for her-2-positive metastatic breast cancer among arabs. Breast Care, 1-7.","journal-title":"Breast Care"}],"event":{"name":"ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences","acronym":"ISAIMS 2022","location":"Amsterdam Netherlands"},"container-title":["Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine Sciences"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570815","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3570773.3570815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:48:43Z","timestamp":1755845323000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":16,"alternative-id":["10.1145\/3570773.3570815","10.1145\/3570773"],"URL":"https:\/\/doi.org\/10.1145\/3570773.3570815","relation":{},"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"2022-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}